المؤلفون: Sood, R., Mancinetti, M., Betticher, D., Cantin, B., Ebneter, A.

المصدر: In Annals of Medicine and Surgery February 2020 50:14-23

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Jeker, B, Novak, U, Mansouri Taleghani, B, Baerlocher, G M, Seipel, K, Mueller, B U, Bigler, M, Betticher, D, Luethi, J-M, Farese, S, Ruefer, A, Pabst, T^{Aff1, IDbmt2017234_cor12}

المصدر: Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 53(2):175-179

المؤلفون: Strasser, F. ^*, Blum, D., von Moos, R., Cathomas, R., Ribi, K., Aebi, S., Betticher, D., Hayoz, S., Klingbiel, D., Brauchli, P., Haefner, M., Mauri, S., Kaasa, S., Koeberle, D.

المصدر: In Annals of Oncology February 2016 27(2):324-332

المؤلفون: König, D, Savic Prince, S, Hayoz, S, Zens, P, Berezowska, S, Jochum, W, Stauffer, E, Braunersreuther, V, Trachsel, B, Thierstein, S, Mark, M, Schmid, S, Curioni-Fontecedro, A, Addeo, A, Opitz, I, Guckenberger, M, Früh, M, Betticher, D C, Ris, H-B, Stupp, R, Rothschild, S I, Bubendorf, L, Pless, M

المساهمون: University of Zurich

المصدر: ESMO open, vol. 8, no. 4, pp. 101595
König, D; Savic Prince, S; Hayoz, S; Zens, P; Berezowska, S; Jochum, W; Stauffer, E; Braunersreuther, V; Trachsel, B; Thierstein, S; Mark, M; Schmid, S; Curioni-Fontecedro, A; Addeo, A; Opitz, I; Guckenberger, M; Früh, M; Betticher, D C; Ris, H-B; Stupp, R; ... (2023). Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. (In Press). ESMO open, 8(4), p. 101595. BMJ 10.1016/j.esmoop.2023.101595 <http://dx.doi.org/10.1016/j.esmoop.2023.101595>

مصطلحات موضوعية: 10255 Clinic for Thoracic Surgery, 570 Life sciences, biology, 610 Medicine & health, 10044 Clinic for Radiation Oncology, PD-L1 expression, chemoradiation, immune checkpoint inhibitor, non-small-cell lung cancer, predictive biomarker

وصف الملف: application/pdf; 2023_Koenig_37441877.pdf - application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa4d7080bd55100876dc0118b69c9bd

المؤلفون: König, D, Schär, S, Vuong, Diem, Guckenberger, Matthias, Furrer, K, Opitz, I, Weder, W, Rothschild, S I, Ochsenbein, A, Zippelius, A, Addeo, A, Mark, M, Eboulet, E I, Hayoz, S, Thierstein, S, Betticher, D C, Ris, H-B, Stupp, R, Curioni-Fontecedro, A, Peters, S, Pless, M, Früh, M

المساهمون: University of Zurich, König, D

المصدر: König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO open, 7(2), p. 100455. Elsevier 10.1016/j.esmoop.2022.100455 <http://dx.doi.org/10.1016/j.esmoop.2022.100455>
ESMO Open

مصطلحات موضوعية: Cancer Research, Lung Neoplasms, 10255 Clinic for Thoracic Surgery, 610 Medicine & health, Docetaxel, 10044 Clinic for Radiation Oncology, Oncology, Carcinoma, Non-Small-Cell Lung, Humans, 2730 Oncology, 1306 Cancer Research, Immunotherapy, Prospective Studies, Cisplatin, Corrigendum, Neoplasm Staging

وصف الملف: application/pdf; 2022_Koenig_35398718.pdf - application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::440c9860be15495f7a56ae43d495bab4
https://boris.unibe.ch/169233/1/1-s2.0-S2059702922000710-main.pdf

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: König, D, Schär, S, Vuong, Diem, Guckenberger, Matthias, Furrer, K, Opitz, I, Weder, W, Rothschild, S I, Ochsenbein, A, Zippelius, A, Addeo, A, Mark, M, Eboulet, E I, Hayoz, S, Thierstein, S, Betticher, D C, Ris, H-B, Stupp, R, Curioni-Fontecedro, A, Peters, S, Pless, M, Früh, M

المساهمون: University of Zurich, König, D

المصدر: König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494 <http://dx.doi.org/10.1016/j.esmoop.2022.100494>

مصطلحات موضوعية: 10255 Clinic for Thoracic Surgery, 2730 Oncology, 1306 Cancer Research, 610 Medicine & health, 10044 Clinic for Radiation Oncology

وصف الملف: application/pdf; 2022_Koenig_35468561.pdf - application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b7758c5e0f3b2ce34c3c65c55ccb36d

المؤلفون: Kamber, C, Zimmerli, S, Suter-Riniker, F, Mueller, B U, Taleghani, B M, Betticher, D, Zander, T, Pabst, T^{Aff1, IDbmt2014290_cor8}

المصدر: Bone Marrow Transplantation: Official journal of the European Society for Blood and Marrow Transplantation. 50(4):573-578

المؤلفون: Ossenkoppele, G.J., Breems, D.A., Stuessi, G., Norden, Y. van, Bargetzi, M., Biemond, B.J., Borne, P.A. von dem, Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J.J.J.W., Jaspers, A., Jongen-Lavrencic, M., Jongh, E. de, Klein, S.K., Klift, M. van der, Kooy, M.V., Maertens, J., Micheaux, L., Poel, M.W.M. van der, Rhenen, A. van, Tick, L., Valk, P., Vekemans, M.C., Velden, W.J.F.M. van der, Weerdt, O. de, Pabst, T., Manz, M., Lowenberg, B., Havelange, Moors, I., Obberg, F. van, Maertens, J.A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Gjertsen, B.T., Passweg, J., Heim, D., Giovanni, S., Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M.G., Loosdrecht, A. van de, Janssen, J.J.W.M., Esser, J.W.J. van, Brouwer, R.E., Lammeren-Venema, D. van, Levin, M.D., Tick, L.W., Legdeur, M.C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J.H., Schouten, H.C., Cornelissen, J., Wouters, B., Raaijmakers, H.G.M., Kuball, J., Dutch-Belgian Hemato-Oncology, Swiss Grp Clinical Canc Res SAKK

المساهمون: Stem Cell Aging Leukemia and Lymphoma (SALL), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Clinical Haematology, CCA - Cancer Treatment and Quality of Life, CCA - Cancer Treatment and quality of life, Hematology laboratory, Hematology, Department of History, International Institute of Social Studies, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie

المصدر: Leukemia, 1751-1759. Nature Publishing Group
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Phases of clinical research, HIGH-DOSE LENALIDOMIDE, ACUTE MYELOID-LEUKEMIA, THERAPY, 03 medical and health sciences, 0302 clinical medicine, Older patients, SDG 3 - Good Health and Well-being, Internal medicine, medicine, 610 Medicine & health, Adverse effect, Lenalidomide, Chemotherapy, business.industry, Intensive treatment, Myeloid leukemia, Hematology, ADULTS, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Cytarabine, business, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6afe4ddcbc8dbf30e80f1d9702e382d
https://research.rug.nl/en/publications/97f14b84-038f-45e9-8e79-0af373ddcd22